Skip to main content

Table 2 Grade 3 or higher toxicities, readmission rates and mortality during the neoadjuvant treatment of patients with pancreatic adenocarcinoma

From: Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients

Grade 3 or higher toxicities Number of studies reporting the studied outcome % 95% confidence interval
Overall 39 36% 27–45%
Hematologic 16 25% 14–38%
Anemia 33 4% 3–6%
Leukopenia 26 25% 18–32%
Lymphopenia 8 13% 4–24%
Neutropenia 38 23% 17–29%
Febrile neutropenia 17 3% 1–5%
Thrombocytopenia 41 7% 5–10%
Non hematologic 17 16% 7–27%
Nausea/vomiting 40 7% 4–10%
Diarrhea 38 4% 2–6%
Anorexia 19 3% 1–6%
Fatigue 26 4% 1–7%
Biliary obstruction/cholangitis 22 5% 3–7%
GI bleed, gastritis, or duodenitis, 14 3% 1–7%
Hospitalization rate 15 21% 14–27%
% of patients completing neoadjuvant therapy 42 90% 87%–93%
Mortality 48 0% 0–1%